Ratan Capital Management LP Acquires New Holdings in IQVIA Holdings Inc. $IQV

Ratan Capital Management LP bought a new stake in IQVIA Holdings Inc. (NYSE:IQV) during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 3,342 shares of the medical research company’s stock, valued at approximately $646,000.

A number of other institutional investors have also made changes to their positions in the stock. Financial Freedom LLC acquired a new position in shares of IQVIA in the 1st quarter worth approximately $25,000. Ascentis Independent Advisors acquired a new stake in IQVIA in the 1st quarter valued at approximately $25,000. International Assets Investment Management LLC purchased a new stake in IQVIA in the fourth quarter valued at approximately $27,000. Compass Financial Management LLC acquired a new position in IQVIA during the second quarter worth $27,000. Finally, Gilpin Wealth Management LLC acquired a new position in IQVIA during the fourth quarter worth $27,000. 89.62% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

IQV has been the topic of several research analyst reports. William Blair upgraded IQVIA to a “strong-buy” rating in a report on Tuesday, July 28th. Wall Street Zen cut IQVIA from a “buy” rating to a “hold” rating in a report on Saturday. Weiss Ratings raised IQVIA from a “hold (c-)” rating to a “hold (c)” rating in a research report on Wednesday, July 15th. Stifel Nicolaus boosted their price target on shares of IQVIA from $220.00 to $276.00 and gave the stock a “buy” rating in a research note on Wednesday, July 29th. Finally, TD Cowen raised their price objective on shares of IQVIA from $233.00 to $288.00 and gave the company a “buy” rating in a research note on Wednesday, July 29th. One research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat.com, IQVIA has an average rating of “Moderate Buy” and a consensus target price of $241.88.

IQVIA Stock Down 0.7%

Shares of NYSE IQV opened at $260.48 on Friday. The stock has a market cap of $42.88 billion, a P/E ratio of 32.32, a PEG ratio of 2.24 and a beta of 1.18. The business’s fifty day simple moving average is $222.14 and its 200-day simple moving average is $189.62. IQVIA Holdings Inc. has a 12-month low of $154.50 and a 12-month high of $265.25. The company has a current ratio of 0.71, a quick ratio of 0.71 and a debt-to-equity ratio of 2.18.

IQVIA (NYSE:IQV) last released its earnings results on Tuesday, July 28th. The medical research company reported $3.15 EPS for the quarter, topping the consensus estimate of $3.03 by $0.12. The firm had revenue of $4.37 billion during the quarter, compared to analysts’ expectations of $4.30 billion. IQVIA had a return on equity of 30.25% and a net margin of 8.10%.IQVIA’s revenue for the quarter was up 8.7% on a year-over-year basis. During the same period in the previous year, the firm posted $2.81 EPS. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. As a group, equities analysts predict that IQVIA Holdings Inc. will post 11.57 EPS for the current fiscal year.

IQVIA declared that its Board of Directors has approved a share repurchase program on Thursday, May 7th that permits the company to buyback $2.00 billion in shares. This buyback authorization permits the medical research company to buy up to 6.8% of its stock through open market purchases. Stock buyback programs are usually an indication that the company’s management believes its stock is undervalued.

Insider Buying and Selling

In related news, insider W Richard Staub sold 5,500 shares of the company’s stock in a transaction that occurred on Monday, August 3rd. The shares were sold at an average price of $232.68, for a total transaction of $1,279,740.00. Following the sale, the insider directly owned 13,312 shares in the company, valued at approximately $3,097,436.16. This represents a 29.24% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Eric Sherbet sold 5,000 shares of the firm’s stock in a transaction that occurred on Wednesday, July 29th. The shares were sold at an average price of $249.16, for a total transaction of $1,245,800.00. Following the completion of the sale, the insider directly owned 20,999 shares in the company, valued at approximately $5,232,110.84. This trade represents a 19.23% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 12,913 shares of company stock valued at $3,098,793. Corporate insiders own 1.70% of the company’s stock.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real?world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real?world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.